Scarica l'app Stockscreener
4.07
0.99%
0.04
Dopo l'orario di chiusura:
4.03
-0.04
-0.98%
Precedente Chiudi:
$4.03
Aprire:
$4.1
Volume 24 ore:
588.84K
Relative Volume:
0.80
Capitalizzazione di mercato:
$263.32M
Reddito:
$500
Utile/perdita netta:
$-54.44M
Rapporto P/E:
-3.4912
EPS:
-1.1658
Flusso di cassa netto:
$-49.91M
1 W Prestazione:
-4.68%
1M Prestazione:
-18.92%
6M Prestazione:
-25.32%
1 anno Prestazione:
-37.67%
Intervallo 1D:
$4.02
$4.145
Intervallo di 1 settimana:
$4.01
$4.25
Portata 52W:
$3.86
$8.48
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.07 | 276.26M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Iniziato | Leerink Partners | Outperform |
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering Corporation (IMRX) stock price, news, quote and history - uk.finance.yahoo.com
Immuneering Corporation Presents Data At 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib?S Mechanisms Designed to Extend Survival in Pancreatic Cancer - marketscreener.com
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering to Present at the ESMO Congress 2026 - The Manila Times
A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. - Stock Titan
Immuneering Corporation(NasdaqGM: IMRX) added to S&P Global BMI Index - marketscreener.com
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
Immuneering at H.C. Wainwright conference: pancreatic cancer push By Investing.com - Investing.com Nigeria
Immuneering at H.C. Wainwright conference: pancreatic cancer push - Investing.com
Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus - Investing.com Canada
Immuneering Stock (IMRX) Opinions on Pancreatic Cancer Drug Presentation - Quiver Quantitative
Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference - Quiver Quantitative
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival - The Manila Times
84% of evaluable pancreatic cancer patients kept or gained weight after three months - Stock Titan
Immuneering to Participate in Upcoming Investor Conferences - Yahoo Finance
H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential - Investing.com India
Immuneering comments on FDA pancreatic cancer drug approval By Investing.com - Investing.com India
Immuneering Highlights FDA Approval in Second-Line Pancreatic Cancer as Phase 3 MAPKeeper 301 Enrolls First-Line Patients - Quiver Quantitative
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - barchart.com
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
HC Wainwright Initiates Immuneering at Buy With $14 Price Target - Yahoo Finance
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Immuneering Corporation (IMRX) Slips 1.37% as Stock Approaches Key Support LevelInsider Buying Alerts - dars.gov.et
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immuneering Corp Azioni (IMRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 15 '26 |
Buy |
4.15 |
6,035 |
25,045 |
382,531 |
| Brakewood Harold Eugene | Chief Business Officer |
Jan 16 '26 |
Buy |
4.76 |
5,250 |
24,990 |
11,050 |
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):